Compare UGI & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UGI | AXSM |
|---|---|---|
| Founded | 1940 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 9.0B |
| IPO Year | N/A | 2015 |
| Metric | UGI | AXSM |
|---|---|---|
| Price | $37.08 | $160.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 17 |
| Target Price | $44.00 | ★ $209.18 |
| AVG Volume (30 Days) | ★ 1.3M | 468.7K |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | ★ 4.14% | N/A |
| EPS Growth | N/A | ★ 38.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.88 | $58.34 |
| Revenue Next Year | $2.27 | $54.30 |
| P/E Ratio | $14.04 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.03 | $86.99 |
| 52 Week High | $41.34 | $191.50 |
| Indicator | UGI | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 43.93 | 34.06 |
| Support Level | $36.86 | $148.14 |
| Resistance Level | $37.43 | $191.13 |
| Average True Range (ATR) | 0.74 | 5.42 |
| MACD | -0.08 | -1.11 |
| Stochastic Oscillator | 38.25 | 3.57 |
UGI Corp is an American holding company that, through its subsidiaries, is involved in the transport and marketing of energy and related services. Its segments include AmeriGas Propane, UGI International, Midstream & Marketing, and Utilities. The AmeriGas Propane segment consists of the propane distribution business. The UGI International segment consists of LPG distribution businesses. The Midstream & Marketing segment consists of energy-related businesses. The Utilities segment consists of the regulated natural gas and electric distribution. The company derives a majority of its revenue from the UGI International segment.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.